首页 | 本学科首页   官方微博 | 高级检索  
     


Effects of Bowman-Birk inhibitor concentrate (BBIC) in patients with benign prostatic hyperplasia
Authors:Malkowicz S B  McKenna W G  Vaughn D J  Wan X S  Propert K J  Rockwell K  Marks S H  Wein A J  Kennedy A R
Affiliation:Department of Surgery, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.
Abstract:
BACKGROUND: The Bowman-Birk inhibitor is a soybean-derived protease inhibitor that has anti-inflammatory and anticarcinogenic activities. METHODS: A Phase I trial of Bowman-Birk inhibitor concentrate (BBIC) in 19 male subjects with benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS) has been performed. RESULTS: The results of the trial indicated that there was no dose-limiting toxicity of BBIC. There was a statistically significant decrease in serum PSA levels in all BBIC-treated patients. Some BBIC-treated patients exhibited a relatively large reduction in serum PSA levels, ranging up to a 43% reduction. There was also a statistically significant decrease in serum triglyceride levels and a decrease in prostate volume in the treated patients. The scores recorded in response to a urinary symptom questionnaire indicated improved urinary activities in the BBIC-treated patients; however, the control subjects exhibited similar improvements in urinary activities during the course of the trial. CONCLUSIONS: The data obtained in this trial, particularly the data suggesting that BBIC treatment may lead to reduced serum PSA levels and reduced prostate volumes, suggest that a Phase II clinical trial of BBIC for the therapy of BPH is warranted.
Keywords:Bowman–Birk inhibitor  benign prostatic hyperplasia (BPH)  prostate specific antigen
本文献已被 PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号